15 September 2021 | News
Waters BioAccord System with ACQUITY Premier brings greater simplicity, accuracy and reproducibility to multi-attribute monitoring of biopharmaceuticals
image credit- businesswire
US-based Waters Corporation has introduced the Waters™ BioAccord™ System with ACQUITY™ Premier, a combination of the Waters BioAccord System and the breakthrough ACQUITY Premier UPLC™ with MaxPeak™ High Performance Surface (HPS) technology.
The integrated high-resolution LC-MS system simplifies multi-attribute monitoring of biotherapeutics by improving analyte recovery and assay-to-assay reproducibility so that regulated laboratories can get needed medicines to patients faster.
The compact, benchtop BioAccord System with ACQUITY Premier features MaxPeak HPS technology and the SmartMS™-enabled ACQUITY RDa™ mass detector allowing analysts of all abilities to monitor critical quality attributes of biotherapeutics and assess the processes that make them, all while decreasing risk, thanks to compliant-ready acquisition and data workflows that deliver consistent data quality from user-to-user and system-to-system.
MaxPeak HPS technology is a hybrid organic/inorganic surface technology that forms a barrier between the sample and the biocompatible metal surfaces of both the UPLC inlet and column.
With automated set-up and guided workflows made possible with SmartMS technology, the BioAccord System with ACQUITY Premier is designed for easy deployment.